CARECLOUD INC (CCLD) Stock Fundamental Analysis
NASDAQ:CCLD - Nasdaq - US14167R1005 - Common Stock - Currency: USD
Taking everything into account, CCLD scores 5 out of 10 in our fundamental rating. CCLD was compared to 37 industry peers in the Health Care Technology industry. CCLD has an average financial health and profitability rating. CCLD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year CCLD has reported negative net income.
CCLD had a positive operating cash flow in the past year.
CCLD had negative earnings in each of the past 5 years.
Of the past 5 years CCLD 4 years had a positive operating cash flow.
1.2 Ratios
CCLD has a Return On Assets of -4.40%. This is in the better half of the industry: CCLD outperforms 75.68% of its industry peers.
CCLD's Return On Equity of -6.33% is fine compared to the rest of the industry. CCLD outperforms 78.38% of its industry peers.
CCLD's Return On Invested Capital of 14.75% is amongst the best of the industry. CCLD outperforms 97.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.4% | ||
| ROE | -6.33% | ||
| ROIC | 14.75% |
ROA(3y)-32.11%
ROA(5y)-24.15%
ROE(3y)-57.71%
ROE(5y)-41.4%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CCLD's Operating Margin of 8.77% is amongst the best of the industry. CCLD outperforms 89.19% of its industry peers.
In the last couple of years the Operating Margin of CCLD has grown nicely.
With a Gross Margin value of 45.11%, CCLD is not doing good in the industry: 62.16% of the companies in the same industry are doing better.
CCLD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.77% | ||
| PM (TTM) | N/A | ||
| GM | 45.11% |
OM growth 3Y59.79%
OM growth 5Y95.05%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.11%
GM growth 5Y4.51%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CCLD is still creating some value.
The number of shares outstanding for CCLD has been increased compared to 1 year ago.
Compared to 5 years ago, CCLD has more shares outstanding
CCLD has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.72 indicates that CCLD is not a great score, but indicates only limited risk for bankruptcy at the moment.
CCLD has a better Altman-Z score (2.72) than 70.27% of its industry peers.
CCLD has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
The Debt to FCF ratio of CCLD (0.03) is better than 89.19% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CCLD is not too dependend on debt financing.
The Debt to Equity ratio of CCLD (0.00) is better than 72.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 2.72 |
ROIC/WACC1.25
WACC11.82%
2.3 Liquidity
A Current Ratio of 1.27 indicates that CCLD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.27, CCLD is in line with its industry, outperforming 43.24% of the companies in the same industry.
CCLD has a Quick Ratio of 1.24. This is a normal value and indicates that CCLD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.24, CCLD is in line with its industry, outperforming 43.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.24 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 85.92% over the past year.
The Revenue has decreased by -5.31% in the past year.
CCLD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.47% yearly.
EPS 1Y (TTM)85.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)-5.31%
Revenue growth 3Y-7.4%
Revenue growth 5Y11.47%
Sales Q2Q%-0.62%
3.2 Future
Based on estimates for the next years, CCLD will show a very strong growth in Earnings Per Share. The EPS will grow by 74.27% on average per year.
Based on estimates for the next years, CCLD will show a small growth in Revenue. The Revenue will grow by 3.57% on average per year.
EPS Next Y157.8%
EPS Next 2Y74.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1.38%
Revenue Next 2Y3.57%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CCLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 14.45, CCLD is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CCLD indicates a rather cheap valuation: CCLD is cheaper than 91.89% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.32, CCLD is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 14.45 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CCLD is valued cheaper than 100.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CCLD indicates a rather cheap valuation: CCLD is cheaper than 97.30% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.34 | ||
| EV/EBITDA | 2.72 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CCLD's earnings are expected to grow with 74.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y74.27%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CCLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.67
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners11.24%
Inst Owner ChangeN/A
Ins Owners37.42%
Ins Owner Change6.3%
Market Cap70.67M
Analysts82
Price Target4.34 (159.88%)
Short Float %1.13%
Short Ratio0.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.92
Dividend Growth(5Y)21.2%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)85.74%
Min EPS beat(2)71.48%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)-23.2%
Min EPS beat(4)-357.52%
Max EPS beat(4)100%
EPS beat(8)4
Avg EPS beat(8)-17.94%
EPS beat(12)8
Avg EPS beat(12)-3.5%
EPS beat(16)12
Avg EPS beat(16)5.11%
Revenue beat(2)0
Avg Revenue beat(2)-1.49%
Min Revenue beat(2)-1.89%
Max Revenue beat(2)-1.1%
Revenue beat(4)0
Avg Revenue beat(4)-1.81%
Min Revenue beat(4)-2.28%
Max Revenue beat(4)-1.1%
Revenue beat(8)0
Avg Revenue beat(8)-4.44%
Revenue beat(12)1
Avg Revenue beat(12)-3.54%
Revenue beat(16)3
Avg Revenue beat(16)-2.25%
PT rev (1m)-4.28%
PT rev (3m)-11.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)61.54%
EPS NY rev (1m)0%
EPS NY rev (3m)145.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.95%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)0.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 14.45 | ||
| P/S | 0.64 | ||
| P/FCF | 5.34 | ||
| P/OCF | 3.42 | ||
| P/B | 1.42 | ||
| P/tB | 5.94 | ||
| EV/EBITDA | 2.72 |
EPS(TTM)-0.2
EYN/A
EPS(NY)0.12
Fwd EY6.92%
FCF(TTM)0.31
FCFY18.73%
OCF(TTM)0.49
OCFY29.21%
SpS2.62
BVpS1.18
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.4% | ||
| ROE | -6.33% | ||
| ROCE | 18.67% | ||
| ROIC | 14.75% | ||
| ROICexc | 16.37% | ||
| ROICexgc | 85.25% | ||
| OM | 8.77% | ||
| PM (TTM) | N/A | ||
| GM | 45.11% | ||
| FCFM | 11.94% |
ROA(3y)-32.11%
ROA(5y)-24.15%
ROE(3y)-57.71%
ROE(5y)-41.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y52.71%
ROICexcg growth 5Y104.32%
ROICexc growth 3Y91.65%
ROICexc growth 5Y92.03%
OM growth 3Y59.79%
OM growth 5Y95.05%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.11%
GM growth 5Y4.51%
F-Score7
Asset Turnover1.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 51.19% | ||
| Cap/Sales | 6.68% | ||
| Interest Coverage | 14.35 | ||
| Cash Conversion | 85.35% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.24 | ||
| Altman-Z | 2.72 |
F-Score7
WACC11.82%
ROIC/WACC1.25
Cap/Depr(3y)74.91%
Cap/Depr(5y)76.9%
Cap/Sales(3y)8.36%
Cap/Sales(5y)8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y157.8%
EPS Next 2Y74.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.31%
Revenue growth 3Y-7.4%
Revenue growth 5Y11.47%
Sales Q2Q%-0.62%
Revenue Next Year1.38%
Revenue Next 2Y3.57%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y342.44%
EBIT growth 3Y47.96%
EBIT growth 5Y117.42%
EBIT Next Year214.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y243.97%
FCF growth 3Y68.43%
FCF growth 5Y21.21%
OCF growth 1Y33.51%
OCF growth 3Y15.69%
OCF growth 5Y22.06%